Literature DB >> 21052935

Neuropsychopharmacological understanding for therapeutic application of morphinans.

Eun-Joo Shin1, Jau-Shyong Hong, Hyoung-Chun Kim.   

Abstract

Morphinans are a class of compounds containing the basic structure of morphine. It is well-known that morphinans possess diverse pharmacological effects on the central nervous system. This review will demonstrate novel neuroprotective effects of several morphinans such as, dextromethorphan, its analogs and naloxone on the models of multiple neurodegenerative disease by modulating glial activation associated with the production of a host of proinflammatory and neurotoxic factors, although dextromethorphan possesses neuropsychotoxic potentials. The neuroprotective effects and the therapeutic potential for the treatment of excitotoxic and inflammatory neurodegenerative diseases, and underlying mechanism of morphinans are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052935      PMCID: PMC3399693          DOI: 10.1007/s12272-010-1009-4

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  96 in total

1.  Dextromethorphan blocks opioid peptide gene expression in the rat hippocampus induced by kainic acid.

Authors:  H C Kim; H W Suh; D Bronstein; G Bing; B Wilson; J S Hong
Journal:  Neuropeptides       Date:  1997-04       Impact factor: 3.286

2.  Effects of dextromethorphan, a nonopioid antitussive, on development and expression of amygdaloid kindled seizures.

Authors:  A Takazawa; P Anderson; W C Abraham
Journal:  Epilepsia       Date:  1990 Sep-Oct       Impact factor: 5.864

3.  3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.

Authors:  Wei Zhang; Eun-Joo Shin; Tongguang Wang; Phil Ho Lee; Hao Pang; Myung-Bok Wie; Won-Ki Kim; Seong-Jin Kim; Wen-Hsin Huang; Yongjun Wang; Wanqin Zhang; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  FASEB J       Date:  2006-12       Impact factor: 5.191

4.  Identification and initial characterization of high-affinity [3H]dextrorphan binding sites in rat brain.

Authors:  P H Franklin; T F Murray
Journal:  Eur J Pharmacol       Date:  1990-07-31       Impact factor: 4.432

5.  Dextromethorphan attenuates post-ischemic hypoperfusion following incomplete global ischemia in the anesthetized rat.

Authors:  F C Tortella; D A Martin; C P Allot; J A Steel; T P Blackburn; B E Loveday; N J Russell
Journal:  Brain Res       Date:  1989-03-13       Impact factor: 3.252

6.  Dextromethorphan and carbetapentane: centrally acting non-opioid antitussive agents with novel anticonvulsant properties.

Authors:  F C Tortella; J M Musacchio
Journal:  Brain Res       Date:  1986-09-24       Impact factor: 3.252

7.  Dimemorfan prevents seizures induced by the L-type calcium channel activator BAY k-8644 in mice.

Authors:  Eun-Joo Shin; Toshitaka Nabeshima; Phil Ho Lee; Won-Ki Kim; Kwang Ho Ko; Jin-Hyeong Jhoo; Wang-Kee Jhoo; Joo Young Cha; Hyoung-Chun Kim
Journal:  Behav Brain Res       Date:  2004-05-05       Impact factor: 3.332

8.  Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents.

Authors:  A H Newman; K Bevan; N Bowery; F C Tortella
Journal:  J Med Chem       Date:  1992-10-30       Impact factor: 7.446

Review 9.  Dextromethorphan and neuromodulation: old drug coughs up new activities.

Authors:  F C Tortella; M Pellicano; N G Bowery
Journal:  Trends Pharmacol Sci       Date:  1989-12       Impact factor: 14.819

10.  Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics.

Authors:  F R Sharp; M Butman; K Aardalen; J Nickolenko; R Nakki; S M Massa; R A Swanson; S M Sagar
Journal:  Psychopharmacol Bull       Date:  1994
View more
  1 in total

1.  Effect of a single dose of dextromethorphan on psychomotor performance and working memory capacity.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Ammar Waham Ashor
Journal:  Indian J Psychol Med       Date:  2012-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.